Molaxole (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Macrogol 3350 is a high‑molecular‑weight polyethylene glycol that is poorly absorbed in the gut. It binds water molecules, creating an osmotic gradient that retains fluid in the intestinal lumen. The resulting increase in stool volume softens the stool and stimulates peristalsis, promoting bowel movements.

The specific dose of Molaxole is determined by the prescribing healthcare professional based on the patient’s condition, age, and response to therapy. Dosage instructions are provided on the product label and should be followed exactly as directed by the prescriber.

Molaxole should be used during pregnancy or lactation only if clearly needed and after a risk‑benefit assessment by the treating physician. Limited data are available, so clinicians weigh potential benefits for constipation relief against any possible risks to the fetus or infant.

To order Molaxole, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with stimulant laxatives, Molaxole’s osmotic mechanism provides gentler, water‑based stool softening with a lower risk of cramping. Unlike some saline laxatives, it contains balanced electrolytes, reducing the likelihood of significant electrolyte disturbances when used as directed.

Molaxole should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

Molaxole is taken orally, usually dissolved in a measured amount of water or another suitable liquid as instructed by the prescriber. The solution should be consumed promptly after preparation, and patients are advised to follow any fluid intake recommendations to support the laxative effect.

Serious risks, though rare, include severe electrolyte imbalance, dehydration, and allergic reactions such as rash, swelling or breathing difficulty. Patients experiencing these symptoms should seek immediate medical attention, and clinicians should monitor electrolyte levels in high‑risk individuals.

Molaxole is contraindicated in patients with known or suspected bowel obstruction, perforation, or severe inflammatory bowel disease. It should also be avoided in individuals with uncontrolled electrolyte disorders or severe renal impairment unless closely supervised by a healthcare professional.